

IN THE CLAIMS:

1. (currently amended) Isolated Oligodeoxynucleotides, presented in the General Formula:

[General Formula]: HKCGTTCRTGTCSGM (SEQ ID NO: 1)

wherein, R represents A or G; S represents C or G; H represents A, T or C; K represents G or T; and M represents C or A.

2. (currently amended) Isolated oligodeoxynucleotides, presented in the following General Formula, at a 5' terminal end and a 3' terminal end:

[General Formula]: DNMHKCGTTCRTGTCSGMYK (SEQ ID NO: 2)

wherein, R represents A or G; S represents C or G; H represents A, T or C; K represents G or T; D represents A, G or T; M represents C or A; M represents C or A; and Y represents C or T.

3-5. (canceled)

6. (previously presented) The oligodeoxynucleotides according to any one of claims 1 and 2, wherein the oligodeoxynucleotides have a phosphodiester bond or phosphorothioate bond between the nucleotides.

7. (currently amended) The oligodeoxynucleotides according to any one of claims 1 and 2, wherein the oligonucleotides are selected from the group consisting of oligonucleotide-is 5'-AGCAGCGTTCGTGTCCGCCT-3' (SEQ ID NO: 3), 5'-AGCAGCGTTCGTGTGCGCCT-3' (SEQ ID NO: 4), 5'-AGCAGCGTTCATGTCGGCCT-3' (SEQ ID NO: 5), 5'-AGCAGCGTTCGTGTCCGCCT-3' (SEQ ID NO: 6), 5'-GTATTGTTCGTGTGCGTCGCT-3' (SEQ ID NO: 7) and 5'-TGACTCGTTCGTGTGCGATG-3' (SEQ ID NO: 8).

8. (previously presented) The oligonucleotide of claim 1, wherein said oligonucleotide is an adjuvant.

9. (previously presented) The oligonucleotide of claim 2 wherein said oligonucleotide is an adjuvant.

10. (canceled)

11. (new) A method for treating atopic dermatitis or protecting normal immune cells when radiotherapy is applied, comprising:

administering to a subject diagnosed with atopic dermatitis a composition comprising an isolated oligonucleotide having the nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 2 and 3 under conditions such that symptoms of atopic dermatitis are reduced.

12. (new) A method for protecting normal immune cells when radiotherapy is applied, comprising:

administering to a subject undergoing radiotherapy in need thereof a composition comprising an isolated oligonucleotide having the nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 2 and 3 under conditions such that viability of said subject's immune cells is increased in the presence of said oligonucleotide.